Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1105 participants.

Also called NCT02930018

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,105 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02930018
Other papers using this trial's data
  • Association of baseline infarct size, reperfusion grade and intracranial hemorrhage in patients undergoing thrombectomy Journal of neurointerventional surgery, 2026-02-16 DOI, PubMed 40122606
  • Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial Lancet (London, England), 2020-03-14 DOI, PubMed 32087818
  • Factors Influencing Nerinetide Effect on Infarct Volume in Patients Without Alteplase in the Randomized ESCAPE-NA1 Trial Stroke, 2025-01 DOI, PubMed 39648909
  • Infarct Evolution on MR-DWI After Thrombectomy in Acute Stroke Patients Randomized to Nerinetide or Placebo: The REPERFUSE-NA1 Study Neurology, 2024-01-23 DOI, PubMed 38165335
  • Infarcts in a New Territory: Insights From the ESCAPE-NA1 Trial Stroke, 2023-06 DOI, PubMed 37082967

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, Germany, Ireland, South Korea, Sweden, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02930018. Randomized; quadruple masking; primary purpose treatment. Start 2017-03-01 (actual); primary completion 2019-11-20 (actual). Results posted on 2020-12-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke
Acronym
ESCAPE-NA1
Condition
Stroke, Acute
Intervention (Drug)
Nerinetide (NA-1), 2.6 mg/kg
Intervention (Drug)
Placebo
Lead sponsor
NoNO Inc. (class: industry)
Collaborator
University of Calgary (class: other)

Record details

Record id
cardio:ct-nct02930018
Content hash
056dabf66f5ebfb4b261cc2c86e2df1fa717cca0a159d8907167d6ca0c39c161